Identification of Brain ECM Binding Variable Lymphocyte Receptors Using Yeast Surface Display.
Biopanning
Blood–brain barrier
Extracellular matrix
Neuropathologies
Variable lymphocyte receptor (VLR)
Yeast surface display
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
28
4
2022
pubmed:
29
4
2022
medline:
3
5
2022
Statut:
ppublish
Résumé
Extracellular matrix (ECM) is a rich mixture of proteins and glycans secreted by cells. This includes typical ECM structures such as collagen and heparin as well as glycosylated, secreted proteins such as growth factors and peptidases. Certain components of ECM are ubiquitous among all tissue; however, each biological tissue also displays unique variations that can be identified using biopanning techniques. Here we describe using a variable lymphocyte receptor (VLR) yeast surface display library to identify selective binders to brain ECM by combining ECM biopanning with a rapid ELISA-based screen using clonal VLRs isolated directly from the yeast surface. Finally, potential ECM-binding candidates can be verified by immunostaining murine brain sections with VLRs released from the yeast surface. These methods provide a framework for the identification of tissue-selective ECM-binding VLRs using yeast surface display techniques and could easily be adapted for other binding scaffolds or ECM from other tissues.
Identifiants
pubmed: 35482194
doi: 10.1007/978-1-0716-2285-8_13
doi:
Substances chimiques
Collagen
9007-34-5
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
235-248Informations de copyright
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Frantz C, Stewart KM, Weaver VM (2010) The extracellular matrix at a glance. J Cell Sci 123(Pt 24):4195–4200. https://doi.org/10.1242/jcs.023820
doi: 10.1242/jcs.023820
pubmed: 21123617
pmcid: 2995612
Yue B (2014) Biology of the extracellular matrix: an overview. J Glaucoma 23(8 Suppl 1):S20–S23. https://doi.org/10.1097/IJG.0000000000000108
doi: 10.1097/IJG.0000000000000108
pubmed: 25275899
Bonnans C, Chou J, Werb Z (2014) Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol 15(12):786–801. https://doi.org/10.1038/nrm3904
doi: 10.1038/nrm3904
pubmed: 25415508
pmcid: 4316204
Colley KJ, Varki A, Kinoshita T (2015) Cellular organization of glycosylation. In: Varki A, Cummings RD et al (eds) Essentials of glycobiology. Cold Spring Harbor Press, Cold Spring Harbor, pp 41–49. https://doi.org/10.1101/glycobiology.3e.004
doi: 10.1101/glycobiology.3e.004
Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ (2010) Structure and function of the blood-brain barrier. Neurobiol Dis 37(1):13–25. https://doi.org/10.1016/j.nbd.2009.07.030
doi: 10.1016/j.nbd.2009.07.030
pubmed: 19664713
Davies DC (2002) Blood-brain barrier breakdown in septic encephalopathy and brain tumours. J Anat 200(6):639–646
doi: 10.1046/j.1469-7580.2002.00065.x
Obermeier B, Verma A, Ransohoff RM (2016) The blood-brain barrier. Handb Clin Neurol 133:39–59. https://doi.org/10.1016/B978-0-444-63432-0.00003-7
doi: 10.1016/B978-0-444-63432-0.00003-7
pubmed: 27112670
Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, Giannini C, Burns TC, Kizilbash SH, Laramy JK, Swanson KR, Kaufmann TJ, Brown PD, Agar NYR, Galanis E, Buckner JC, Elmquist WF (2018) Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro Oncol 20(2):184–191. https://doi.org/10.1093/neuonc/nox175
doi: 10.1093/neuonc/nox175
pubmed: 29016900
Umlauf BJ, Shusta EV (2019) Exploiting BBB disruption for the delivery of nanocarriers to the diseased CNS. Curr Opin Biotechnol 60:146–152. https://doi.org/10.1016/j.copbio.2019.01.013
doi: 10.1016/j.copbio.2019.01.013
pubmed: 30849699
pmcid: 6728237
Yang Y, Rosenberg GA (2011) Blood-brain barrier breakdown in acute and chronic cerebrovascular disease. Stroke 42(11):3323–3328. https://doi.org/10.1161/STROKEAHA.110.608257
doi: 10.1161/STROKEAHA.110.608257
pubmed: 21940972
pmcid: 3584169
Umlauf BJ, Clark PA, Lajoie JM, Georgieva JV, Bremner S, Herrin BR, Kuo JS, Shusta EV (2019) Identification of variable lymphocyte receptors that can target therapeutics to pathologically exposed brain extracellular matrix. Sci Adv 5(5):eaau4245. https://doi.org/10.1126/sciadv.aau4245
doi: 10.1126/sciadv.aau4245
pubmed: 31106264
pmcid: 6520025
Han BW, Herrin BR, Cooper MD, Wilson IA (2008) Antigen recognition by variable lymphocyte receptors. Science 321(5897):1834–1837. https://doi.org/10.1126/science.1162484
doi: 10.1126/science.1162484
pubmed: 18818359
pmcid: 2581502
Herrin BR, Alder MN, Roux KH, Sina C, Ehrhardt GRA, Boydston JA, Turnbough CL, Cooper MD (2008) Structure and specificity of lamprey monoclonal antibodies. Proc Natl Acad Sci U S A 105(6):2040–2045. https://doi.org/10.1073/pnas.0711619105
doi: 10.1073/pnas.0711619105
pubmed: 18238899
pmcid: 2542867
Herrin BR, Cooper MD (2010) Alternative adaptive immunity in jawless vertebrates. J Immunol 185(3):1367–1374. https://doi.org/10.4049/jimmunol.0903128
doi: 10.4049/jimmunol.0903128
pubmed: 20660361
Hirano M, Guo P, McCurley N, Schorpp M, Das S, Boehm T, Cooper MD (2013) Evolutionary implications of a third lymphocyte lineage in lampreys. Nature 501(7467):435–438. https://doi.org/10.1038/nature12467
doi: 10.1038/nature12467
pubmed: 23934109
pmcid: 3901013
Collins BC, Gunn RJ, McKitrick TR, Cummings RD, Cooper MD, Herrin BR, Wilson IA (2017) Structural insights into VLR fine specificity for blood group carbohydrates. Structure 25(11):1667–1678.e1664. https://doi.org/10.1016/j.str.2017.09.003
doi: 10.1016/j.str.2017.09.003
pubmed: 28988747
pmcid: 5677568
Hong X, Ma MZ, Gildersleeve JC, Chowdhury S, Barchi JJ Jr, Mariuzza RA, Murphy MB, Mao L, Pancer Z (2013) Sugar-binding proteins from fish: selection of high affinity “lambodies” that recognize biomedically relevant glycans. ACS Chem Biol 8(1):152–160. https://doi.org/10.1021/cb300399s
doi: 10.1021/cb300399s
pubmed: 23030719
Boder ET, Wittrup KD (1997) Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 15(6):553–557. https://doi.org/10.1038/nbt0697-553
doi: 10.1038/nbt0697-553
pubmed: 9181578
Wang XX, Shusta EV (2005) The use of scFv-displaying yeast in mammalian cell surface selections. J Immunol Methods 304(1–2):30–42. https://doi.org/10.1016/j.jim.2005.05.006
doi: 10.1016/j.jim.2005.05.006
pubmed: 16099466
Boder ET, Midelfort KS, Wittrup KD (2000) Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci U S A 97(20):10701–10705. https://doi.org/10.1073/pnas.170297297
doi: 10.1073/pnas.170297297
pubmed: 10984501
pmcid: 27086
Burns ML, Malott TM, Metcalf KJ, Puguh A, Chan JR, Shusta EV (2016) Pro-region engineering for improved yeast display and secretion of brain derived neurotrophic factor. Biotechnol J 11(3):425–436. https://doi.org/10.1002/biot.201500360
doi: 10.1002/biot.201500360
pubmed: 26580314
Tillotson BJ, Cho YK, Shusta EV (2013) Cells and cell lysates: a direct approach for engineering antibodies against membrane proteins using yeast surface display. Methods 60(1):27–37. https://doi.org/10.1016/j.ymeth.2012.03.010
doi: 10.1016/j.ymeth.2012.03.010
pubmed: 22449570
Tillotson BJ, Lajoie JM, Shusta EV (2015) Yeast display-based antibody affinity maturation using detergent-solubilized cell lysates. Methods Mol Biol 1319:65–78. https://doi.org/10.1007/978-1-4939-2748-7_4
doi: 10.1007/978-1-4939-2748-7_4
pubmed: 26060070
pmcid: 5076467